September 8, 2014 (Shareholders Foundation) - An investigation on behalf of current long-term investors in shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) concerning potential breaches of fiduciary duties by certain directors and officers of Ampio Pharmaceuticals was announced.

The investigation by a law firm concerns whether certain Ampio Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Ampio Pharmaceuticals Inc reported that its annual Net Loss increased from $11.59 million in 2012 to $24.01 million in 2013.Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) grew from $2.88 per share to as high as $10.05 per share in October 2013.

On August 21, 2014, Ampio Pharmaceuticals Inc announced that due to temperature deviations below product specifications during shipments to the Ampion STEP Study clinical sites, release of data will be delayed.

Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) declined from $7.46 per share on August 20, 2014 to $.83 per share on August 22, 2014 and continued to decline to as low as $3.79 per share on Sept. 5, 2014.